Aclasta is a once-yearly injection of the bisphosphonate zoledronic acid that offers much improved adherence compared with oral bisphosphonates. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Elaine Dennison comments on its ...
The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Methods A patient-level state-transition model was developed to predict the outcome of patients with osteoporosis who have experienced a previous ...
Zoledronic acid: a once-yearly injection for osteoporosisAclasta is a once-yearly injection of the bisphosphonate zoledronic acid that offers much improved adherence compared with oral bisphosphonates. In our New products review Steve Chaplin presents the clinical data relating to its efficacy and ...
Osteoporosis InternationalMoriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness anal- ysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28(6):1939-1950Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection ...
Osteoporosis InternationalMoriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness anal- ysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28(6):1939-1950Moriwaki K, Mouri M, Hagino H. Cost-effectiveness analysis of once-yearly injection ...